What is Outcomes4me?
Outcomes4me operates at the intersection of healthcare technology and oncology, utilizing artificial intelligence and machine learning to provide personalized, regulatory-aligned guidance to cancer patients. As the first digital platform to integrate directly with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, the company serves as a critical bridge between complex clinical standards and patient-facing digital tools. By enabling users to securely manage health data and receive physician-reviewed treatment insights, Outcomes4me addresses a significant market gap in patient empowerment and clinical transparency. The platform's ability to synthesize genetic testing options and clinical trial data into actionable intelligence positions it as a high-authority player in the health-tech ecosystem, effectively scaling the delivery of high-quality, personalized medical information.
How much funding has Outcomes4me raised?
Outcomes4me has raised a total of $37.8M across 4 funding rounds:
Other Financing Round
$4.7M
Debt
$149K
Series A
$12M
Other Financing Round
$21M
Other Financing Round (2020): $4.7M with participation from Sierra Ventures, Merstal, and Asset Management Ventures
Debt (2021): $149K led by PPP
Series A (2021): $12M supported by Sierra Ventures, asset management ventures, Northpond Ventures, Merstal, and IRA Capital
Other Financing Round (2025): $21M featuring Northpond Ventures, Silica Investments, and Sierra Ventures
Key Investors in Outcomes4me
Sierra Ventures
A Silicon Valley-based venture capital firm that focuses on early-stage technology startups, providing strategic support from product-market fit through to scale-up and exit.
Northpond Ventures
A venture firm dedicated to advancing science and technology, with a specific focus on supporting breakthrough innovations that create significant, positive impacts on humanity.
Silica Investments
A California-based investment firm operating within the venture capital and private equity sectors, focusing on high-growth potential enterprises.
What's next for Outcomes4me?
With this major enterprise-level funding, Outcomes4me is expected to scale its operational footprint and enhance its AI-driven diagnostic support capabilities. The strategic focus will likely shift toward expanding its clinical trial matching engine and deepening its integration with major oncology networks. By maintaining a rigorous adherence to regulatory standards while scaling its digital infrastructure, the company is well-positioned to capture a larger share of the personalized medicine market. Future growth will likely involve broadening its therapeutic focus areas and strengthening partnerships with healthcare providers to ensure that evidence-based guidance remains at the forefront of the patient care journey.
See full Outcomes4me company page
